NARS-3′
NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC50 of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.
For research use only. We do not sell to patients.
- CAS No.: 2702589-46-4
- Formula: C15H11NaO8S
- Molecular Weight:374.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
NARS-3′ (0-100 μM) exhibits dose-dependent inhibition on XO activity[1].
NARS-3′ (0-40 μM) can bind to the active site of XO and compete with xanthine substrates during the catalytic process[1].
NARS-3′ could cause the conformational changes in XO[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Potassium oxonate (250 mg/kg) injected the male Kunming mice (4 weeks)[1].
-
Dosage:0.3 % carboxymethyl cellulose sodium solution
-
Administration:Oral gavage (i.g.); once daily for a week
-
Result:Reduced serum UA levels to 56.26 μM and reduced XO activity to 9.21 U/L.
Lowered serum CRE levels to 7.85 μM and reduce pathological damage to the kidneys.
Chemical Information
-
CAS No. 2702589-46-4
-
Molecular Weight 374.30
-
Formula C15H11NaO8S
-
SMILES
O=C1CC(OC2=CC(O)=CC(O)=C12)C3=CC(S(=O)(O[Na])=O)=C(C=C3)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)